Rangering i aksjer
#19830
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Handel Alpha Cognition Inc (ACOG)
Pris ACOG pris med markedsverdi på B
Markedsverdi av Alpha Cognition Inc(ACOG)
Markedsverdi: $149.33M
Per August 2026 har Alpha Cognition Inc en markedsverdi på $149.33M. Dette gjør Alpha Cognition Inc til det 19830th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Alpha Cognition Inc fra 2024 til 2026
ACOG sammenlignet med topp 5 mest populære stocks
| Pris på ACOG |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.152T
|
+3,450,396.58%
|
|
|
|
|
$4.537T
|
+3,038,233.58%
|
|
|
|
|
$4.169T
|
+2,791,489.37%
|
|
|
|
|
$3.642T
|
+2,439,094.36%
|
|
|
|
|
$2.805T
|
+1,878,142.65%
|
